Kenner/Lewis:Genetics and Genomics for Nursing,1eChapter 1: Genetics and Genomics: Definitions and TrendsCase StudyQuestionsGenetic Biomarker (GB) testing is becoming more popular as the cost and relevancy ofpharmacogenomics testing becomes better known and easily applicable to clinical practice. A sitereferencing required, recommended, or for information only testing is available on the FDA websiteat www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Thiswill assist in answering the following questions:A registered nurse is assigned to care for three patients who are receiving medications that areknown to be associated with genetic traits or GB(s) that could alter the effect of the drug. Identify ifthe GB has required, recommended, or for information only status for testing.This activity contains 3 questions.1.L.L. is a 52-year-old Caucasian female being treated with Herceptin for her recently diagnosedher2/neu positive breast cancer.Answer:Required. The breast cancer tumor must be tested for the presence of the her2/neureceptor in order to receive Herceptin.2.R.N. is a 62-year-old male with a new diagnosis of rheumatoid arthritis and has beenprescribed Celebrex 200mg b.i.d.Answers:Recommended if PM status suspected. Poor metabolizers (PM) of Celebrex should havedosage reduced by 50%. If this patient is a PM the dose should be reduced to 100mg b.i.d. andmonitored for side effects.www.accessdata.fda.gov/drugsatfda_docs/label/2011/020998s033,021156s003lbl.pdf3.M.G. is a 26-year-old Ethiopian new mom who delivered her first child by a caesarean section.She was prescribed codeine 30mg p.o. and is breastfeeding her newborn.Answers: Because of her Ethiopian ancestry, M.G. could be an Ultra-rapid metabolizer and shouldreceive a non-codeine analgesic.www.accessdata.fda.gov/drugsatfda_docs/label/2012/022402s003lbl.pdfPreview Mode
This document has 360 pages. Sign in to access the full document!
